Literature DB >> 10813723

Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7.

A V D'Amico1, R Whittington, S B Malkowicz, D Schultz, J E Tomaszewski, A Wein.   

Abstract

BACKGROUND: Early (< or = 2 years) prostate specific antigen (PSA) failure after radical prostatectomy (RP) has been shown to predict for distant failure. After excluding patients with the pathologic predictors of early PSA failure, an analysis of PSA failure free (bNED) survival was performed to identify patients who may benefit from the use of postprostatectomy radiation therapy (RT).
METHODS: Of 1,028 patients treated with RP for clinically localized prostate carcinoma between 1989 and 1999, 862 (84%) had either organ confined (OC), specimen confined (SC), or margin positive disease with negative seminal vesicles (SV) and a prostatectomy Gleason score < or = 7. A Cox regression multivariate analysis was performed in these patients evaluating the ability of the extent of extracapsular extension (ECE) (into but not through the capsule, SC focal ECE, SC established ECE, margin positive) and prostatectomy Gleason score (2-6 vs. 7) to predict time to postoperative PSA failure.
RESULTS: SC focal ECE (P = 0.0017), SC established ECE (P < 0.0001), and margin positive disease (P < 0.0001) were significant predictors of time to postoperative PSA failure, whereas prostatectomy Gleason score and disease extending into but not through the capsule were not. Five-year bNED rates were 90%, 88%, 69%, 45%, and 33% for patients with OC, into but not through capsule, SC focal ECE, SC established ECE, and margin positive prostate carcinoma, respectively.
CONCLUSIONS: Patients with SC ECE or margin positive prostate carcinoma and a prostatectomy Gleason score < or = 7 with no evidence of SV invasion may benefit from adjuvant postoperative RT.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10813723     DOI: 10.1002/(sici)1097-0142(20000501)88:9<2110::aid-cncr17>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Radical versus postoperative radiotherapy for localized prostate cancer: a 10-year experience of an academic hospital.

Authors:  Emilios E Pakos; Pericles G Tsekeris; Evita J Pitouli; Stergiani P Gritzeli; Evangelos Briasoulis
Journal:  World J Urol       Date:  2006-05-10       Impact factor: 4.226

2.  Impact of the extent of extraprostatic extension defined by Epstein's method in patients with negative surgical margins and negative lymph node invasion.

Authors:  T Maubon; N Branger; C Bastide; G Lonjon; K-A Harvey-Bryan; P Validire; S Giusiano; D Rossi; X Cathelineau; F Rozet
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-07-12       Impact factor: 5.554

3.  The influence of extent of surgical margin positivity on prostate specific antigen recurrence.

Authors:  R E Emerson; M O Koch; T D Jones; J K Daggy; B E Juliar; L Cheng
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

4.  Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes.

Authors:  Andreas G Wibmer; Ines Nikolovski; Joshua Chaim; Yulia Lakhman; Robert A Lefkowitz; Evis Sala; Sigrid V Carlsson; Samson W Fine; Michael W Kattan; Hedvig Hricak; Hebert Alberto Vargas
Journal:  Radiology       Date:  2021-12-21       Impact factor: 11.105

5.  Prognostic factors for failure after prostatectomy.

Authors:  Gregory P Swanson; Joseph W Basler
Journal:  J Cancer       Date:  2010-12-07       Impact factor: 4.207

6.  Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer.

Authors:  Clare Verrill; Lucia Cerundolo; Chad Mckee; Michael White; Christiana Kartsonaki; Eve Fryer; Emma Morris; Simon Brewster; Indrika Ratnayaka; Luke Marsden; Hans Lilja; Ruth Muschel; Xin Lu; Freddie Hamdy; Richard J Bryant
Journal:  Oncotarget       Date:  2016-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.